Glucosteril Fresenius Kabi (Glucose Monohydrate)

Glucosteril is employed in clinical settings where rapid provision of glucose is required.

• Supplementing carbohydrate calories in parenteral nutrition regimens.
• Preventing hypoglycemia during peri‑operative periods.
• Providing an immediate energy source for patients unable to receive enteral nutrition.
• Supporting metabolic demands in critically ill or trauma patients.
• Used as a diluent or carrier for compatible intravenous medications when glucose is needed.

When administered intravenously, Glucosteril may be associated with a range of observed effects.

Common

• Transient increase in blood glucose levels.
• Mild hyperosmolarity at high infusion rates.
• Local irritation at the infusion site.
• Nausea or vomiting if administered rapidly.

Serious

• Severe hyperglycemia requiring medical intervention.
• Electrolyte disturbances such as hyponatremia.
• Fluid overload leading to pulmonary edema.
• Allergic reactions including rash, urticaria, or anaphylaxis.

Clinicians should observe several precautions when prescribing Glucosteril to ensure patient safety.

• Assess baseline blood glucose and adjust infusion rate accordingly.
• Monitor serum electrolytes, especially sodium and potassium, during therapy.
• Use caution in patients with renal or cardiac insufficiency due to risk of fluid overload.
• Avoid rapid bolus administration; prefer controlled infusion.
• Verify compatibility with other IV solutions before mixing.
• Consider pregnancy status; data are limited.
• Document infusion parameters in the patient record.

Glucosteril can interact with other intravenous agents, influencing glucose balance or solution compatibility.

Avoid

• Co‑administration with high‑dose insulin infusions without close glucose monitoring.
• Mixing with calcium‑containing solutions that may precipitate.

Use with caution

• Concurrent use of diuretics that affect electrolyte status.
• Administration alongside hypertonic saline solutions.
• Use with catecholamines that can increase glucose production.
• Combining with other carbohydrate‑rich IV fluids may cause hyperglycemia.